Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry - A tutorial.

El Amrani M, Donners AAM, Hack CE, Huitema ADR, van Maarseveen EM.

Anal Chim Acta. 2019 Nov 8;1080:22-34. doi: 10.1016/j.aca.2019.05.076. Epub 2019 Jun 11. Review.

PMID:
31409472
2.

Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium.

Bruin MAC, Rosing H, Lucas L, Wang J, Huitema ADR, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121723. doi: 10.1016/j.jchromb.2019.121723. Epub 2019 Jul 18.

PMID:
31352204
3.

Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children.

Szanto CL, Langenhorst J, de Koning C, Nierkens S, Bierings M, Huitema ADR, Lindemans CA, Boelens JJ.

Biol Blood Marrow Transplant. 2019 Jul 22. pii: S1083-8791(19)30478-1. doi: 10.1016/j.bbmt.2019.07.022. [Epub ahead of print]

PMID:
31344451
4.

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Langenhorst JB, van Kesteren C, van Maarseveen EM, Dorlo TPC, Nierkens S, Lindemans CA, de Witte MA, van Rhenen A, Raijmakers R, Bierings M, Kuball J, Huitema ADR, Boelens JJ.

Blood Adv. 2019 Jul 23;3(14):2179-2187. doi: 10.1182/bloodadvances.2018029421.

5.

Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort).

Pandit R, Cianci D, Ter Hark SE, Winter-van Rossum I, Ebdrup BH, Broberg BV, Garcia-Portilla MP, Bobes J, Vinkers CH, Kahn RS, Guloksuz S, Huitema ADR, Luykx JJ.

Acta Psychiatr Scand. 2019 Sep;140(3):283-290. doi: 10.1111/acps.13074. Epub 2019 Jul 19.

PMID:
31323113
6.

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, Attarbaschi A, Baruchel A, Fagioli F, Klingebiel T, De Moerloose B, Palumbo G, von Stackelberg A, Kaspers GJL, Huitema ADR.

Clin Pharmacokinet. 2019 Jul 16. doi: 10.1007/s40262-019-00803-y. [Epub ahead of print]

PMID:
31313068
7.

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH.

Cancer Chemother Pharmacol. 2019 Sep;84(3):487-499. doi: 10.1007/s00280-019-03905-3. Epub 2019 Jul 15. Review.

8.

Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model.

Ter Heine R, Kane SP, Huitema ADR, Krasowski MD, van Maarseveen EM.

Br J Clin Pharmacol. 2019 Jul 3. doi: 10.1111/bcp.14053. [Epub ahead of print]

PMID:
31269540
9.

Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia.

Favié LMA, Groenendaal F, van den Broek MPH, Rademaker CMA, de Haan TR, van Straaten HLM, Dijk PH, van Heijst A, Simons SHP, Dijkman KP, Rijken M, Zonnenberg IA, Cools F, Zecic A, van der Lee JH, Nuytemans DHGM, van Bel F, Egberts TCG, Huitema ADR; on behalf of the PharmaCool study group.

Neonatology. 2019;116(2):154-162. doi: 10.1159/000499330. Epub 2019 Jun 28.

10.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma.

Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 10;174:561-566. doi: 10.1016/j.jpba.2019.06.034. Epub 2019 Jun 24.

PMID:
31255856
11.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.

de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S.

Clin Cancer Res. 2019 Sep 15;25(18):5466-5474. doi: 10.1158/1078-0432.CCR-17-2299. Epub 2019 Jun 19.

PMID:
31217201
12.

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

Braal CL, Beijnen JH, Koolen SLW, Oomen-de Hoop E, Steeghs N, Jager A, Huitema ADR, Mathijssen RHJ.

J Clin Oncol. 2019 Aug 1;37(22):1980-1981. doi: 10.1200/JCO.19.00418. Epub 2019 Jun 18. No abstract available.

PMID:
31211599
13.

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

Crombag MBS, Haanen JBAG, Baas P, Beijnen JH, Huitema ADR.

J Geriatr Oncol. 2019 Jun 14. pii: S1879-4068(19)30118-3. doi: 10.1016/j.jgo.2019.06.001. [Epub ahead of print] No abstract available.

PMID:
31208830
14.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N.

Eur J Clin Pharmacol. 2019 Sep;75(9):1309-1318. doi: 10.1007/s00228-019-02704-2. Epub 2019 Jun 7.

PMID:
31175385
15.

Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study.

Arnamo AH, Huitema AD, Beijnen JH, Nuijen B.

J Oncol Pharm Pract. 2019 Jun 2:1078155219850297. doi: 10.1177/1078155219850297. [Epub ahead of print]

PMID:
31156055
16.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).

Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof AAFA, Hartemink KJ, Grootscholten C, Snaebjornsson P, Retel VP, van Tinteren H, Vanhoutvin S, van der Noort V, Houwink A, Hahn C, Huitema ADR, Lahaye M, Los M, van den Barselaar P, Imhof O, Aalbers A, van Dam GM, van Etten B, Wijnhoven BPL, Luyer MDP, Boerma D, van Sandick JW.

BMC Cancer. 2019 May 6;19(1):420. doi: 10.1186/s12885-019-5640-2.

17.

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.

van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, Voest EE.

Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. No abstract available.

PMID:
31038154
18.

Predictive Value of Microdose Pharmacokinetics.

van Nuland M, Rosing H, Huitema ADR, Beijnen JH.

Clin Pharmacokinet. 2019 Apr 27. doi: 10.1007/s40262-019-00769-x. [Epub ahead of print] Review.

PMID:
31030372
19.

Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.

van de Meeberg MM, Schultheiss JPD, Oldenburg B, Fidder HH, Huitema ADR.

Digestion. 2019 Apr 23:1-17. doi: 10.1159/000499331. [Epub ahead of print]

20.

Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.

Bastida C, Soy D, Ruiz-Esquide V, Sanmartí R, Huitema ADR.

Br J Clin Pharmacol. 2019 Aug;85(8):1710-1718. doi: 10.1111/bcp.13954. Epub 2019 Jun 17.

PMID:
30958574
21.

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH.

Cancer Med. 2019 Apr;8(4):1406-1415. doi: 10.1002/cam4.2003. Epub 2019 Feb 22.

22.

Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia.

Favié LMA, Groenendaal F, van den Broek MPH, Rademaker CMA, de Haan TR, van Straaten HLM, Dijk PH, van Heijst A, Dudink J, Dijkman KP, Rijken M, Zonnenberg IA, Cools F, Zecic A, van der Lee JH, Nuytemans DHGM, van Bel F, Egberts TCG, Huitema ADR; PharmaCool study group.

PLoS One. 2019 Feb 14;14(2):e0211910. doi: 10.1371/journal.pone.0211910. eCollection 2019.

23.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR.

Drugs Aging. 2019 Apr;36(4):379-385. doi: 10.1007/s40266-019-00643-2.

PMID:
30734241
24.

Tamoxifen and pregnancy: an absolute contraindication?

Schuurman TN, Witteveen PO, van der Wall E, Passier JLM, Huitema ADR, Amant F, Lok CAR.

Breast Cancer Res Treat. 2019 May;175(1):17-25. doi: 10.1007/s10549-019-05154-7. Epub 2019 Feb 1. Review.

PMID:
30707336
25.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, Huitema ADR.

Clin Genitourin Cancer. 2019 Apr;17(2):e383-e386. doi: 10.1016/j.clgc.2018.12.004. Epub 2018 Dec 19. No abstract available.

26.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6.

PMID:
30617624
27.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:234-239. doi: 10.1016/j.jchromb.2018.11.030. Epub 2018 Nov 30.

PMID:
30530116
28.

Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.

Groenland SL, Katz D, Huitema ADR, Steeghs N.

BMC Cancer. 2018 Dec 3;18(1):1200. doi: 10.1186/s12885-018-5043-9.

29.

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.

Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW.

Clin Pharmacokinet. 2019 May;58(5):651-658. doi: 10.1007/s40262-018-0719-5.

30.

Innate Immune Recovery Predicts CD4+ T Cell Reconstitution after Hematopoietic Cell Transplantation.

de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, Boelens JJ.

Biol Blood Marrow Transplant. 2019 Apr;25(4):819-826. doi: 10.1016/j.bbmt.2018.10.013. Epub 2018 Oct 23.

PMID:
30359735
31.

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ, van Kesteren C, Huitema ADR.

Clin Pharmacokinet. 2019 May;58(5):627-637. doi: 10.1007/s40262-018-0715-9.

32.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168-175. doi: 10.1038/s41391-018-0096-z. Epub 2018 Oct 2.

PMID:
30279580
33.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

de Vries Schultink AHM, Huitema ADR, Beijnen JH.

Breast. 2018 Dec;42:38-40. doi: 10.1016/j.breast.2018.08.100. Epub 2018 Aug 22.

PMID:
30153552
34.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.

PMID:
30068020
35.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769. doi: 10.1111/bcp.13719. Epub 2018 Sep 25.

36.

Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry.

El Amrani M, Szanto CL, Hack CE, Huitema ADR, Nierkens S, van Maarseveen EM.

Anal Bioanal Chem. 2018 Sep;410(23):5849-5858. doi: 10.1007/s00216-018-1198-0. Epub 2018 Jun 25.

37.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.

Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N.

Clin Pharmacokinet. 2019 Mar;58(3):299-308. doi: 10.1007/s40262-018-0683-0. Review.

PMID:
29862467
38.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR.

Invest New Drugs. 2018 Dec;36(6):1006-1015. doi: 10.1007/s10637-018-0593-x. Epub 2018 May 5.

39.

Solubility and bioavailability improvement of pazopanib hydrochloride.

Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B.

Int J Pharm. 2018 Jun 10;544(1):181-190. doi: 10.1016/j.ijpharm.2018.04.037. Epub 2018 Apr 19.

PMID:
29680279
40.

Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients.

Herbrink M, Nuijten M, Nuijen B, Huitema ADR, Beijnen JH, Hendriks VM, Blanken P, Janmohamed A, van den Brink W.

J Clin Psychopharmacol. 2018 Jun;38(3):212-217. doi: 10.1097/JCP.0000000000000862.

PMID:
29620701
41.

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM.

Clin Pharmacokinet. 2018 Nov;57(11):1421-1433. doi: 10.1007/s40262-018-0642-9.

42.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH.

Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. Epub 2018 Apr 16.

43.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

de Vries Schultink AHM, Boekhout AH, Gietema JA, Burylo AM, Dorlo TPC, van Hasselt JGC, Schellens JHM, Huitema ADR.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):431-442. doi: 10.1007/s10928-018-9579-8. Epub 2018 Feb 10.

44.

Development of a nomogram for the estimation of long-term adherence to clozapine therapy using neutrophil fluorescence.

Man WH, Pérez-Pitarch A, Wilting I, Heerdink ER, van Solinge WW, Egberts ACG, Huitema ADR.

Br J Clin Pharmacol. 2018 Jun;84(6):1228-1237. doi: 10.1111/bcp.13546. Epub 2018 Apr 2.

45.

Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations.

van Berlo-van de Laar IRF, Brummelhuis WJ, Imholz ALT, Schellens JH, Huitema ADR, Jansman FGA.

J Clin Pharm Ther. 2018 Aug;43(4):574-577. doi: 10.1111/jcpt.12661. Epub 2018 Jan 5.

PMID:
29315736
46.

Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.

Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yagüe J, Sanmartí R, Huitema ADR, Soy D.

Br J Clin Pharmacol. 2018 Apr;84(4):716-725. doi: 10.1111/bcp.13500. Epub 2018 Feb 7.

47.

Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.

van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ.

Eur J Surg Oncol. 2018 Feb;44(2):220-227. doi: 10.1016/j.ejso.2017.10.216. Epub 2017 Nov 15.

PMID:
29258720
48.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR.

Ther Drug Monit. 2018 Apr;40(2):230-236. doi: 10.1097/FTD.0000000000000479.

PMID:
29256969
49.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET.

Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N.

J Nucl Med. 2018 Jun;59(6):973-979. doi: 10.2967/jnumed.117.195800. Epub 2017 Nov 24.

50.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2018 Apr;32(4). doi: 10.1002/bmc.4147. Epub 2017 Dec 19.

PMID:
29165815

Supplemental Content

Loading ...
Support Center